title: In vitro radiosensitizing effects of ultrasmall gadolinium based particles on tumour cells.
abstract: Since radiotherapy is widely used in cancer treatment, it is essential to develop strategies which lower the irradiation burden while increasing efficacy and become efficient even in radio resistant tumors. Our new strategy is relying on the development of solid hybrid nanoparticles based on rare-earth such as gadolinium. In this paper, we then evidenced that gadolinium-based particles can be designed to enter efficiently into the human glioblastoma cell line U87 in quantities that can be tuned by modifying the incubation conditions. These sub-5 nm particles consist in a core of gadolinium oxide, a shell of polysiloxane and are functionalized by diethylenetriaminepentaacetic acid (DTPA). Although photoelectric effect is maximal in the [10-100 keV] range, such particles were found to possess efficient in-vitro radiosensitizing properties at an energy of 660 keV by using the "single-cell gel electrophoresis comet assay," an assay that measures the number of DNA damage that occurs during irradiation. Even more interesting, the particles have been evidenced by MTT assays to be also efficient radiosensitizers at an energy of 6 MeV for doses comprised between 2 and 8 Gy. The properties of the gadolinium-based particles give promising opening to a particle-assisted radio-therapy by using irradiation systems already installed in the majority of hospitals.
authors.affiliation: LPCML, UMR 5620 CNRS, Université de Lyon, Université Claude Bernard, Bât. Berthollet, 2ème étage, 22 rue Gaston Berger 69622 Villeurbanne Cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: Mowat
authors.forename: A
authors.initials: A
authors.lastname: Mignot
authors.forename: W
authors.initials: W
authors.lastname: Rima
authors.forename: F
authors.initials: F
authors.lastname: Lux
authors.forename: O
authors.initials: O
authors.lastname: Tillement
authors.forename: C
authors.initials: C
authors.lastname: Roulin
authors.forename: M
authors.initials: M
authors.lastname: Dutreix
authors.forename: D
authors.initials: D
authors.lastname: Bechet
authors.forename: S
authors.initials: S
authors.lastname: Huger
authors.forename: L
authors.initials: L
authors.lastname: Humbert
authors.forename: M
authors.initials: M
authors.lastname: Barberi-Heyob
authors.forename: M T
authors.initials: MT
authors.lastname: Aloy
authors.forename: E
authors.initials: E
authors.lastname: Armandy
authors.forename: C
authors.initials: C
authors.lastname: Rodriguez-Lafrasse
authors.forename: G
authors.initials: G
authors.lastname: Le Duc
authors.forename: S
authors.initials: S
authors.lastname: Roux
authors.forename: P
authors.initials: P
authors.lastname: Perriat
mesh_terms: D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology*; D045744:Cell Line, Tumor; D020552:Comet Assay; D004249:DNA Damage; D005682:Gadolinium; D005909:Glioblastoma / Q000235:genetics / Q000473:pathology*; D006801:Humans; D066298:In Vitro Techniques; D053758:Nanoparticles; D011838:Radiation-Sensitizing Agents
chemical_list: D011838:Radiation-Sensitizing Agents; D005682:Gadolinium